Table 4.
Demographic and clinical factors associated with having a low MCS or PCS component summary score
| Mental component summary score | Physical component summary score | |||||
|---|---|---|---|---|---|---|
| N, % (n = 74) | Crude RR (95% CI) | Adjusted RR (95% CI) | N, % (n = 75) | Crude RR (95% CI) | Adjusted RR (95% CI) | |
| Adverse event | ||||||
| Adverse event not reported | 31/91 (34.1%) | 1.00 | 1.00 | 35/91 (38.5%) | 1.00 | 1.00 |
| Adverse event reported | 43/58 (74.1%) | 2.18 (1.57–3.01) | 2.24 (1.53–3.27) | 40/58 (69.0%) | 1.79 (1.31–2.45) | 1.52 (1.07–2.18) |
| Sex | ||||||
| Male | 39/82 (47.6%) | 1.00 | 1.00 | 41/82 (46.1%) | 1.00 | 1.00 |
| Female | 35/67 (52.2%) | 1.10 (0.79–1.52) | 1.23 (0.81–1.84) | 34/67 (54.8%) | 1.01 (0.74–1.40) | 1.10 (0.71–1.68) |
| Age at treatment initiation (years) | ||||||
| 18–35 | 39/74 (52.7%) | 1.00 | 1.00 | 37/74 (50.0%) | 1.00 | 1.00 |
| > 35+ | 35/75 (46.7%) | 0.89 (0.64–1.23) | 0.91 (0.62–1.34) | 38/75 (50.7%) | 1.01 (0.74–1.40) | 0.86 (0.56–1.31) |
| Education | ||||||
| Secondary school and higher | 67/135 (49.6%) | 1.00 | 71/135 (52.6%) | 1.00 | ||
| Primary school or less | 7/14 (50.0%) | 1.01 (0.58–1.75) | 4/14 (28.6%) | 0.54 (0.23–1.27) | ||
| Employment Status | ||||||
| Unemployed | 45/85 (52.9%) | 1.00 | 45/85 (52.9%) | 1.00 | ||
| Employed | 28/63 (44.4%) | 0.84 (0.60–1.18) | 29/63 (44.4%) | 0.87 (0.62–1.22) | ||
| Resistance Pattern | ||||||
| RIF resistant by Xpert MTB/RIF | 21/38 (55.2%) | 1.00 | 1.00 | 21/38 (55.2%) | 1.00 | 1.00 |
| RIF mono-resistant (INH sensitive) | 30/67 (44.8%) | 0.81 (0.55–1.20) | 0.89 (0.55–1.45) | 29/67 (43.3%) | 0.78 (0.53–1.17) | 0.88 (0.55–1.41) |
| MDR-TB (RIF and INH resistant) | 14/32 (43.8%) | 0.79 (0.49–1.29) | 1.09 (0.67–1.78) | 16/32 (50.0%) | 0.90 (0.58–1.42) | 1.15 (0.66–1.99) |
| Missing | 9/12 (75.0%) | 1.36 (0.88–2.09) | 0.98 (0.59–1.64) | 9/12 (75.0%) | 1.36 (0.88–2.09) | 1.26 (0.81–1.95) |
| HIV Status | ||||||
| HIV negative | 11/27 (40.7%) | 1.00 | 13/27 (48.1%) | 1.00 | ||
| HIV positive and on ART | 45/94 (47.9%) | 1.18 (0.71–1.94) | 44/94 (46.8%) | 0.97 (0.62–1.52) | ||
| HIV positive not on ART | 14/22 (63.6%) | 1.56 (0.90–2.72) | 15/22 (68.2%) | 1.42 (0.87–2.30) | ||
| Missing | 4/6 (66.7%) | 1.64 (0.79–3.39) | 3/6 (50.0%) | 1.04 (0.42–2.54) | ||
| Baseline CD4# | ||||||
| ≤ 250 (n = 78) | 39/78 (50.0%) | 1.00 | 41/78 (52.6%) | 1.00 | 1.00 | |
| > 250 (n = 31) | 16/31 (51.6%) | 1.03 (0.69–1.55) | 12/31 (38.7%) | 0.74 (0.45–1.21) | 0.82 (0.45–1.50) | |
| CD4 count unknown (n = 7) | 4/7 (57.1%) | 1.14 (0.58–2.56) | 6/7 (85.7%) | 1.63 (1.13–2.36) | 1.04 (0.55–1.94) | |
| Indications for DR-TB regimen | ||||||
| Standard regimen (long- or short-course) | 55/107 (51.4%) | 1.14 (0.78–1.66) | 1.49 (1.00–2.24) | 54/107 (50.5%) | 1.01 (0.71–1.44) | |
| Individualized regimen (injection free) | 19/42 (45.2%) | 1.0 | 1.0 | 21/42 (50.0%) | 1.0 | |
| Duration of DR-TB treatment (months) | ||||||
| ≤ 6 months | 49/66 (74.2%) | 2.46 (1.72–3.53) | 2.27 (1.53–3.35) | 44/66 (66.7%) | 1.78 (1.29–2.48) | 1.70 (1.11–2.61) |
| > 6 months | 25/83 (30.1%) | 1.0 | 1.0 | 31/83 (37.3%) | 1.0 | 1.0 |
| Duration of ART (months)& | ||||||
| ≤ 6 months (n = 14) | 10/14 (71.4%) | 1.91 (1.21–3.02) | 1.46 (0.96–2.23) | 7/14 (50.0%) | 1.24 (0.68–2.27) | 0.98 (0.51–1.89) |
| > 6 months (n = 67) | 25/67 (31.3%) | 1.0 | 1.0 | 27/67 (40.3%) | 1.0 | 1.0 |
| ART start date unknown (n = 13) | 10/13 (76.9%) | 2.06 (1.34–3.18) | 1.58 (0.96–2.59) | 10/13 (76.9%) | 1.91 (1.26–2.90) | 1.58 (0.96–2.60) |
| Anaemia | ||||||
| None or mild (Hb ≥11.0 g/dL) | 29/64 (45.3%) | 1.00 | 31/64 (48.8%) | 1.00 | ||
| Moderate (8–10.9 g/dL) or severe (< 8 g/dL) | 14/26 (53.8%) | 1.19 (0.76–1.86) | 14/26 (53.8%) | 1.11 (0.72–1.72) | ||
| Missing | 31/59 (52.5%) | 1.16 (0.81–1.67) | 30/59 (50.8%) | 1.05 (0.73–1.50) | ||
| Weight at diagnosis (kg) | ||||||
| < 50 kg | 52/103 (50.5%) | 1.00 | 51/103 (49.5%) | 1.00 | ||
| ≥ 50 kg | 17/37 (45.9%) | 0.91 (0.61–1.36) | 18/37 (48.6%) | 0.98 (0.67–1.44) | ||
| Missing | 5/9 (55.6%) | 1.10 (0.59–2.04) | 6/9 (66.7%) | 1.35 (0.81–2.23) | ||
| Referring Facility | ||||||
| Outpatient | 47/100 (47.0%) | 1.00 | 48/100 (48.0%) | 1.00 | ||
| Inpatient | 27/49 (55.1%) | 1.17 (0.84–1.63) | 27/49 (55.1%) | 1.15 (0.83–1.59) | ||
| Patient Category | ||||||
| New | 47/90 (52.2%) | 1.00 | 47/90 (52.2%) | 1.00 | ||
| Previously treated | 13/36 (36.1%) | 0.69 (0.43–1.12) | 13/36 (36.1%) | 0.69 (0.43–1.12) | ||
| Missing | 14/23 (60.9%) | 1.17 (0.79–1.71) | 15/23 (65.2%) | 1.25 (0.87–1.79) | ||
| TB Type | ||||||
| PTB and EPTB or EPTB only | 11/24 (45.8%) | 1.00 | 12/24 (45.8%) | 1.00 | ||
| PTB and not reported | 63/125 (50.4%) | 1.10 (0.69–1.76) | 63/125 (50.4%) | 1.01 (0.65–1.56) | ||
| Smear Microscopy | ||||||
| Negative | 49/99 (49.5%) | 1.00 | 48/99 (48.5%) | 1.00 | ||
| Positive | 10/26 (38.5%) | 0.78 (0.46–1.32) | 12/26 (46.2%) | 0.95 (0.60–1.51) | ||
| Missing | 15/24 (62.5%) | 1.26 (0.87–1.83) | 15/24 (62.5%) | 1.29 (0.89–1.87) | ||
PTB pulmonary tuberculosis, EPTB extra pulmonary tuberculosis, DR-TB drug-resistant TB, MDR-TB multi-drug resistant TB, RR-TB rifampicin-resistant tuberculosis, RIF rifampicin, INH isoniazid, Hb hemoglobin
# Among patients who are HIV positive (n = 116)
& Among patients who are HIV positive and on ART (n = 94)
a Standard long-course = 6 months of injectable kanamycin and 18–24 months of oral moxifloxacin, ethionamide, terizidone, and pyrazinamide
b Individualized long-course = bedaquiline was introduced as a substitute for kanamycin in the standard long-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)
c Standard short-course = 4 to 6-month intensive phase of kanamycin, moxifloxacin, ethionamide, clofazimine, pyrazinamide and high-dose isoniazid followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol
d Individualized short-course = bedaquiline was introduced as a substitute for kanamycin in the standard short-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)